...
首页> 外文期刊>Experimental Biology and Medicine: Journal of the Society for Experimental Biology and Medicine >Preservation of the cardiac function in infarcted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds.
【24h】

Preservation of the cardiac function in infarcted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds.

机译:通过将可注射的纤维蛋白支架移植到脂肪干细胞上,可以保护梗死大鼠心脏的心脏功能。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cell-based therapy can improve cardiac function but is limited by the low cell retention and survival within ischemic tissues. Injectable cardiac tissue engineering aims to support cell-based therapies and enhance their efficacy for cardiac diseases. So far, no research has been devoted to studying the usefulness of the combination of fibrin glue (as scaffold) and adipose-derived stem cells (ADSCs) to treat myocardial infarction. In our study, the rat ADSCs were isolated from subcutaneous adipose tissues. The surface phenotype of these cells was analyzed by flow cytometry. The fibrin glue was then co-injected with ADSCs into the left ventricular wall of rat infarction models. The structure and functional consequences of transplantation were determined by detailed histological analysis and echocardiography. Most cultured ADSCs expressed CD105 and CD90, and were negative for CD34 and CD45. After injection, both the 24-h cell retention and four-week graft size were significantly higher and larger in the Fibrin + ADSCs group than those of the ADSCs group alone (P < 0.01). The heart function improved significantly in the Fibrin + ADSCs group compared with that of the ADSCs group four weeks after transplantation (P < 0.01). In addition, the arteriole densities within the infarcted area improved significantly in the Fibrin + ADSCs group compared with those in the ADSCs group four weeks after transplantation (P < 0.01). In conclusion, the ADSCs with the fibrin glue has the therapeutic potential to improve the function of infarcted hearts. The method of in situ injectable tissue engineering combining fibrin glue with ADSCs is promising clinically.
机译:基于细胞的疗法可以改善心脏功能,但受到缺血组织中低细胞滞留和存活的限制。可注射的心脏组织工程旨在支持基于细胞的疗法并增强其对心脏病的疗效。迄今为止,还没有研究致力于研究纤维蛋白胶(如支架)和脂肪干细胞(ADSCs)联合治疗心肌梗死的有效性。在我们的研究中,大鼠ADSCs是从皮下脂肪组织中分离出来的。通过流式细胞仪分析这些细胞的表面表型。然后将纤维蛋白胶与ADSCs共注射到大鼠梗塞模型的左心室壁中。通过详细的组织学分析和超声心动图确定移植的结构和功能后果。大多数培养的ADSC表达CD105和CD90,而CD34和CD45阴性。注射后,纤维蛋白+ ADSCs组的24 h细胞保留和四周移植物大小均明显高于单独的ADSCs组(P <0.01)。纤维蛋白+ ADSCs组的心脏功能与移植后4周的ADSCs组相比有显着改善(P <0.01)。此外,与ADSCs组相比,纤维蛋白+ ADSCs组梗死区域内的小动脉密度在移植后四周显着改善(P <0.01)。总之,带有纤维蛋白胶的ADSC具有改善梗塞心脏功能的治疗潜力。将纤维蛋白胶与ADSCs结合在一起的原位注射组织工程方法在临床上很有希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号